These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27716734)

  • 1. Lessons from acute HIV infection.
    Robb ML; Ananworanich J
    Curr Opin HIV AIDS; 2016 Nov; 11(6):555-560. PubMed ID: 27716734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
    Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
    J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
    Harrer T; Plettenberg A; Arastéh K; Van Lunzen J; Fätkenheuer G; Jaeger H; Janssens M; Burny W; Collard A; Roman F; Loeliger A; Koutsoukos M; Bourguignon P; Lavreys L; Voss G
    Vaccine; 2014 May; 32(22):2657-65. PubMed ID: 24144472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV vaccines: can CD4+ T cells be of help?
    Van Braeckel E; Leroux-Roels G
    Hum Vaccin Immunother; 2012 Dec; 8(12):1795-8. PubMed ID: 22906935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed differentiation of potent effector CD8
    Takata H; Buranapraditkun S; Kessing C; Fletcher JL; Muir R; Tardif V; Cartwright P; Vandergeeten C; Bakeman W; Nichols CN; Pinyakorn S; Hansasuta P; Kroon E; Chalermchai T; O'Connell R; Kim J; Phanuphak N; Robb ML; Michael NL; Chomont N; Haddad EK; Ananworanich J; Trautmann L;
    Sci Transl Med; 2017 Feb; 9(377):. PubMed ID: 28202771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transmitted/Founder Viruses Rapidly Escape from CD8+ T Cell Responses in Acute Hepatitis C Virus Infection.
    Bull RA; Leung P; Gaudieri S; Deshpande P; Cameron B; Walker M; Chopra A; Lloyd AR; Luciani F
    J Virol; 2015 May; 89(10):5478-90. PubMed ID: 25740982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy.
    Valor L; Navarro J; Carbone J; Rodríguez-Sáinz C; Gil J; López F; Fernández-Cruz E;
    Vaccine; 2008 May; 26(22):2738-45. PubMed ID: 18433946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy.
    Tung FY; Tung JK; Pallikkuth S; Pahwa S; Fischl MA
    Vaccine; 2016 Apr; 34(19):2225-32. PubMed ID: 27002500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection.
    Herasimtschuk A; Downey J; Nelson M; Moyle G; Mandalia S; Sikut R; Adojaan M; Stanescu I; Gotch F; Imami N
    Vaccine; 2014 Dec; 32(51):7005-7013. PubMed ID: 25454870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine-induced T cells control reversion of AIDS virus immune escape mutants.
    Fernandez CS; Smith MZ; Batten CJ; De Rose R; Reece JC; Rollman E; Venturi V; Davenport MP; Kent SJ
    J Virol; 2007 Apr; 81(8):4137-44. PubMed ID: 17251297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV replication leads to skewed maturation of CD8-positive T-cell responses in infected children.
    Montesano C; Anselmi A; Palma P; Bernardi S; Cicconi R; Mattei M; Castelli-Gattinara G; Ciccozzi M; Colizzi V; Amicosante M
    New Microbiol; 2010 Oct; 33(4):303-9. PubMed ID: 21213588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.
    Lévy Y; Gahéry-Ségard H; Durier C; Lascaux AS; Goujard C; Meiffrédy V; Rouzioux C; El Habib R; Beumont-Mauviel M; Guillet JG; Delfraissy JF; Aboulker JP;
    AIDS; 2005 Feb; 19(3):279-86. PubMed ID: 15718838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eradication of HIV-1 latent reservoirs through therapeutic vaccination.
    Pankrac J; Klein K; Mann JFS
    AIDS Res Ther; 2017 Sep; 14(1):45. PubMed ID: 28893280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elucidating the elite: mechanisms of control in HIV-1 infection.
    O'Connell KA; Bailey JR; Blankson JN
    Trends Pharmacol Sci; 2009 Dec; 30(12):631-7. PubMed ID: 19837464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short communication: HIV antigen-specific reactivation of HIV infection from cellular reservoirs: implications in the settings of therapeutic vaccinations.
    Shete A; Thakar M; Singh DP; Gangakhedkar R; Gaikwad A; Pawar J; Paranjape R
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):835-43. PubMed ID: 21936714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.
    Gudmundsdotter L; Wahren B; Haller BK; Boberg A; Edbäck U; Bernasconi D; Buttò S; Gaines H; Imami N; Gotch F; Lori F; Lisziewicz J; Sandström E; Hejdeman B
    Vaccine; 2011 Jul; 29(33):5558-66. PubMed ID: 21300092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions.
    Graziani GM; Angel JB
    J Int AIDS Soc; 2015; 18(1):20497. PubMed ID: 26561337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD8+ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles.
    Koofhethile CK; Ndhlovu ZM; Thobakgale-Tshabalala C; Prado JG; Ismail N; Mncube Z; Mkhize L; van der Stok M; Yende N; Walker BD; Goulder PJR; Ndung'u T
    J Virol; 2016 Aug; 90(15):6818-6831. PubMed ID: 27194762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The independent effect of drug resistance on T cell activation in HIV infection.
    Hunt PW; Deeks SG; Bangsberg DR; Moss A; Sinclair E; Liegler T; Bates M; Tsao G; Lampiris H; Hoh R; Martin JN
    AIDS; 2006 Mar; 20(5):691-9. PubMed ID: 16514299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.